Premium
Evaluation of Anti‐Diabetic Potential of a Novel Soluble Silicate in Rodent Models
Author(s) -
Vattem Dhiraj Anil,
Maitin Vatsala,
Richardson Charles Reed
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.859.3
Subject(s) - metformin , medicine , diabetes mellitus , endocrinology , triglyceride , rodent , antioxidant , in vivo , chemistry , pharmacology , cholesterol , biology , biochemistry , ecology , microbiology and biotechnology
Emerging research suggests that they may have micronutrient and health promoting functions. However, their mechanism of action is not clearly understood. We have previously shown that one species of soluble silicate [Na8.2Si4.4H9.7O17.6] has antioxidant properties and can modulate gene function relevant to metabolic regulation. Here we present results from an in vivo evaluation of this silicate species on progression and management of diabetes in rodent models. Co‐supplementation of silicates at dosage of 3.5mM with metformin (250–1000 mg) on diabetic and cardiovascular parameters was evaluated in ZDF‐ Lepr fa /Crl male rats and BKS.Cg‐ m +/+ Lepr db /J mouse for 6–18 weeks. Our results indicate that with a moderately high staring glucose (300–400 mg/dl) co‐treatment of 3.5mM with 500 mg metformin had a significant effect on reduction of blood glucose, HbA1c, cholesterol, triglyceride and body weight after 8–11 weeks of treatment and was associated with lower incidences of cataracts. There was also a significant improvement in liver function as indicated by lower AST and ALT levels. Gross necroscopy indicated no abnormality in liver and kidneys. Results suggest a potential anti‐diabetic function of [Na8.2Si4.4H9.7O17.6], further investigation is necessary to understand mechanism of action.